238 related articles for article (PubMed ID: 28234347)
1. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS; He J; Tytarenko R; Deshpande S; Patel P; Bailey M; Stein CK; Stephens O; Weinhold N; Petty N; Steward D; Rasche L; Bauer M; Ashby C; Peterson E; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Schinke C; Zangari M; van Rhee F; Barlogie B; Mughal TI; Davies FE; Morgan GJ; Walker BA
Blood Cancer J; 2017 Feb; 7(2):e535. PubMed ID: 28234347
[TBL] [Abstract][Full Text] [Related]
2. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.
Stein CK; Pawlyn C; Chavan S; Rasche L; Weinhold N; Corken A; Buros A; Sonneveld P; Jackson GH; Landgren O; Mughal T; He J; Barlogie B; Bergsagel PL; Davies FE; Walker BA; Morgan GJ
Oncotarget; 2017 Apr; 8(17):27854-27867. PubMed ID: 28427158
[TBL] [Abstract][Full Text] [Related]
3. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
4. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
[TBL] [Abstract][Full Text] [Related]
5. TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.
Hara Y; Shiba N; Yoshida K; Yamato G; Kaburagi T; Shiraishi Y; Ohki K; Shiozawa Y; Kawamura M; Kawasaki H; Sotomatsu M; Takizawa T; Matsuo H; Shimada A; Kiyokawa N; Tomizawa D; Taga T; Ito E; Horibe K; Miyano S; Adachi S; Taki T; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2023 Jul; 62(7):412-422. PubMed ID: 37102302
[TBL] [Abstract][Full Text] [Related]
6. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
[TBL] [Abstract][Full Text] [Related]
7. Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22.
Holzmann C; Koczan D; Loening T; Rommel B; Bullerdiek J
Anticancer Res; 2017 May; 37(5):2233-2237. PubMed ID: 28476787
[TBL] [Abstract][Full Text] [Related]
8. Biallelic and monoallelic deletion of the RB1 promoter in six isogenic clonal H9 hESC lines.
Döpper H; Horstmann M; Menges J; Bozet M; Kanber D; Steenpass L
Stem Cell Res; 2020 May; 45():101779. PubMed ID: 32268247
[TBL] [Abstract][Full Text] [Related]
9. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
10. The
Berry JL; Polski A; Cavenee WK; Dryja TP; Murphree AL; Gallie BL
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31683923
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
[TBL] [Abstract][Full Text] [Related]
12. [Genetic analysis results of patients with a retinoblastoma refractory to systemic chemotherapy].
Ruiz del Río N; Abelairas Gómez JM; Alonso García de la Rosa FJ; Peralta Calvo JM; de las Heras Martín A
Arch Soc Esp Oftalmol; 2015 Sep; 90(9):414-20. PubMed ID: 25817468
[TBL] [Abstract][Full Text] [Related]
13. Superficial acral fibromyxoma: clinicopathological, immunohistochemical, and molecular study of 11 cases highlighting frequent Rb1 loss/deletions.
Agaimy A; Michal M; Giedl J; Hadravsky L; Michal M
Hum Pathol; 2017 Feb; 60():192-198. PubMed ID: 27825811
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the RB Pathway With Inactivation of RB1 Characterize Glioblastomas With a Primitive Neuronal Component.
Chkheidze R; Raisanen J; Gagan J; Richardson TE; Pinho MC; Raj K; Achilleos M; Slepicka C; White CL; Evers BM; Patel TR; Malter JS; Hatanpaa KJ
J Neuropathol Exp Neurol; 2021 Dec; 80(12):1092-1098. PubMed ID: 34850045
[TBL] [Abstract][Full Text] [Related]
15. Generation of two H1 hESC sublines carrying deletions of RB1 exon 1/promoter in heterozygous or compound heterozygous state.
Menges J; Cremanns M; Steenpass L
Stem Cell Res; 2019 Aug; 39():101517. PubMed ID: 31404748
[TBL] [Abstract][Full Text] [Related]
16. Detection of Aberrant DNA Methylation Patterns in the RB1 Gene.
Anwar SL; Lehmann U
Methods Mol Biol; 2018; 1726():35-47. PubMed ID: 29468542
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side-by-side comparison in karyotypically normal cells.
Andersson N; Saba KH; Magnusson L; Nilsson J; Karlsson J; Nord KH; Gisselsson D
Genes Chromosomes Cancer; 2023 Feb; 62(2):93-100. PubMed ID: 36124964
[TBL] [Abstract][Full Text] [Related]
18. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.
Kooi IE; Mol BM; Massink MP; Ameziane N; Meijers-Heijboer H; Dommering CJ; van Mil SE; de Vries Y; van der Hout AH; Kaspers GJ; Moll AC; Te Riele H; Cloos J; Dorsman JC
Sci Rep; 2016 Apr; 6():25264. PubMed ID: 27126562
[TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53, ZNF750, and RB1 typify ocular sebaceous carcinoma.
Bao Y; Selfridge JE; Wang J; Zhao Y; Cui J; Guda K; Wang Z; Zhu Y
J Genet Genomics; 2019 Jun; 46(6):315-318. PubMed ID: 31278009
[No Abstract] [Full Text] [Related]
20. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
